JP5305710B2 - ドルゾラミド塩酸塩点眼液 - Google Patents
ドルゾラミド塩酸塩点眼液 Download PDFInfo
- Publication number
- JP5305710B2 JP5305710B2 JP2008094363A JP2008094363A JP5305710B2 JP 5305710 B2 JP5305710 B2 JP 5305710B2 JP 2008094363 A JP2008094363 A JP 2008094363A JP 2008094363 A JP2008094363 A JP 2008094363A JP 5305710 B2 JP5305710 B2 JP 5305710B2
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic solution
- dorzolamide hydrochloride
- eye
- eye irritation
- dorzolamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002997 ophthalmic solution Substances 0.000 title claims description 56
- 229940054534 ophthalmic solution Drugs 0.000 title claims description 52
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 title claims description 51
- 229960002506 dorzolamide hydrochloride Drugs 0.000 title claims description 51
- 239000004480 active ingredient Substances 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 4
- SNHBGEDHHQFRLN-XPUUQOCRSA-N CCN[C@H]1C[C@H](C)Sc2sc(cc12)S(N)(=O)=O Chemical compound CCN[C@H]1C[C@H](C)Sc2sc(cc12)S(N)(=O)=O SNHBGEDHHQFRLN-XPUUQOCRSA-N 0.000 claims 1
- 206010015946 Eye irritation Diseases 0.000 description 25
- 231100000013 eye irritation Toxicity 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000003889 eye drop Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 229940012356 eye drops Drugs 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 10
- 230000007935 neutral effect Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000010412 Glaucoma Diseases 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 230000004410 intraocular pressure Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- -1 sodium chloride) Chemical compound 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- XHERSKWRZXCTTK-UHFFFAOYSA-N 2h-thiopyran-2-sulfonamide Chemical compound NS(=O)(=O)C1SC=CC=C1 XHERSKWRZXCTTK-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- SSULTCPIIYRGFQ-UHFFFAOYSA-N tosufloxacin tosylate hydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F SSULTCPIIYRGFQ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
試験に用いた主要な使用機器を以下に示す。
pHメーター: D-22(株式会社 堀場製作所)
電子天秤: AT261(メトラートレド株式会社)
浸透圧計: 5004型(株式会社 アムコ)
液体クロマトグラフ装置: W2487型(ウォーターズ株式会社)
液体クロマトグラフ装置のデータ処理装置: Millennium32(ウォーターズ株式会社)
基本処方を以下のようにする。
ドルゾラミド塩酸塩:1.12%
塩化ナトリウム:0.6%
0.1N 水酸化ナトリウム液(水酸化ナトリウム水溶液): 適量
精製水: 適量
浸透圧比: 約1.0
100mL調製する場合を以下に示す。
精製水80mL中に塩化ナトリウム0.6g及びドルゾラミド塩酸塩1.12%を加えて溶かす。pHの調整は、0.1N 水酸化ナトリウム液の滴加にて行うものとし、pH調整後に精製水で全量100mLとする。調製液を孔径0.22μmのメンブランフィルター(ミリポア社製)で無菌ろ過し、5mLのプラスチック点眼瓶に充填し、プラスチック製中栓及びプラスチック製キャップで装栓し、点眼液を得るものとする。
<眼刺激性試験>
健常人3名の片眼に、各点眼液を1滴ずつそれぞれ点眼し、そのときの刺激性を以下に示す4段階の基準で評価し、スコア化した。被験者3名が評価した各点眼液の評価値の平均を刺激係数としてそれぞれ算出した。
―: 何も感じない 0点
±: 違和感あり 1点
+: わずかに刺激がある 2点
++: 痛い 3点
まず、ドルゾラミド塩酸塩を含有しない点眼液(生理食塩水)のpHと眼刺激性の関係を確認した。ドルゾラミド塩酸塩等の有効成分を含有しない点眼液、つまり、浸透圧を約1.0とされた生理食塩水を点眼液として調製し、塩酸若しくは水酸化ナトリウムにて点眼液のpHを以下のように調整した。
点眼液A(生理食塩水A): pH 5.0
点眼液B(生理食塩水B): pH 5.5
点眼液C(生理食塩水C): pH 6.0
点眼液D(生理食塩水D): pH 6.5
これら点眼液A,B,C、Dにて眼刺激試験を行うと、いずれの点眼液でも、眼刺激の評価(刺激係数)が0となった。つまり、点眼液のpHが酸性領域〜中性領域であっても、点眼時に眼刺激がないことが確認された。
次に、ドルゾラミド塩酸塩点眼液の眼刺激性を確認するために、以下に示すように、ドルゾラミド塩酸塩の含有量は同じでpHのみ異なる4種類の点眼液を調製し、4種類の点眼液と比較例のpHと眼刺激の関係をスコア化した(表1参照)。
点眼液1:基本処方のpHを6.1に調整した処方
点眼液2:基本処方のpHを6.4に調整した処方
点眼液3:基本処方のpHを6.8に調整した処方
点眼液4:基本処方のpHを7.8に調整した処方
比較例: ドルゾラミド塩酸塩を含有する市販品(萬有製薬株式会社)
ドルゾラミド塩酸塩: 1.12%含有、他に、塩化ベンザルコニウム、ヒドロキシエチルセルロース、D−マンニトール、クエン酸ナトリウム及び塩酸含有
pH: 5.7
浸透圧比: 約1.0
ドルゾラミド塩酸塩を有効成分とする点眼液のpHを中性領域とした場合のドルゾラミド塩酸塩の安定性(残存性)について試験を行った。ここでは、調製した点眼液を長期保存した際、pH及びドルゾラミド塩酸塩の残存率(残存量)がどのように変化するか測定した。ここで、ドルゾラミド塩酸塩の濃度は、液体クロマトグラフィーにて測定した。なお、ドルゾラミド塩酸塩の残存率は、点眼液調製直後のドルゾラミド塩酸塩の濃度に対する各試験後の点眼液中のドルゾラミド塩酸塩の濃度を百分率にて算出することとした(表2参照)。
保存条件: 摂氏40度
相対湿度25%以下
保存期間: 6ヶ月間
<安定性試験用の点眼液の調製>
ドルゾラミド塩酸塩: 0.56%
塩化ナトリウム: 0.6%
ヒドロキシエチルセルロース: 0.5%
ベンザルコニウム塩化物液10: 0.03%
0.1N 水酸化ナトリウム液: 適量
精製水: 適量
pH: 6.8
Claims (1)
- A.下記化学式で示されるドルゾラミド塩酸塩(化学名:(―)−(4S,6S)―4−エチルアミノー5,6―ジヒドロー6―メチルー4H―チエノ[2,3−b]チオピランー2―スルホンアミド7,7−ジオキシド モノヒドロクロライド)を有効成分とするドルゾラミド塩酸塩点眼液において、
B.前記ドルゾラミド塩酸塩を0.5〜2.0重量%含有し、さらにpHが6.8〜8.5とされることを特徴とするドルゾラミド塩酸塩点眼液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008094363A JP5305710B2 (ja) | 2008-03-31 | 2008-03-31 | ドルゾラミド塩酸塩点眼液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008094363A JP5305710B2 (ja) | 2008-03-31 | 2008-03-31 | ドルゾラミド塩酸塩点眼液 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009242368A JP2009242368A (ja) | 2009-10-22 |
JP5305710B2 true JP5305710B2 (ja) | 2013-10-02 |
Family
ID=41304712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008094363A Active JP5305710B2 (ja) | 2008-03-31 | 2008-03-31 | ドルゾラミド塩酸塩点眼液 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5305710B2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201542196A (zh) * | 2013-08-26 | 2015-11-16 | Rohto Pharma | 眼科用製劑 |
CN110903299A (zh) * | 2018-09-17 | 2020-03-24 | 武汉武药科技有限公司 | 一种盐酸多佐胺的精制方法 |
CN111084758A (zh) * | 2018-10-24 | 2020-05-01 | 武汉武药科技有限公司 | 盐酸多佐胺滴眼液及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3170619B2 (ja) * | 1995-04-20 | 2001-05-28 | 参天製薬株式会社 | 有機アミンを配合したプラノプロフェン点眼液 |
CA2294343A1 (en) * | 1997-06-26 | 1999-01-07 | Merck & Co., Inc. | Method for optimizing retinal and optic nerve health |
JP2004359679A (ja) * | 2003-05-15 | 2004-12-24 | Taisho Pharmaceut Co Ltd | 点眼剤組成物 |
JP5710087B2 (ja) * | 2006-01-18 | 2015-04-30 | 株式会社日本点眼薬研究所 | 点眼液用調製剤 |
-
2008
- 2008-03-31 JP JP2008094363A patent/JP5305710B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2009242368A (ja) | 2009-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008317965B2 (en) | Osmolyte-containing preparation for use in case of dry mucous membranes | |
EP2364137B1 (en) | Pharmaceutical suspension | |
JP5394927B2 (ja) | 自己保存性水性医薬品組成物 | |
TW201100103A (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
EA008005B1 (ru) | Интраназальный препарат ротиготина | |
EA008165B1 (ru) | Композиции для лечения простуды | |
JPH0696521B2 (ja) | 眼局所投与用眼圧降下剤 | |
WO2007007894A1 (ja) | キサンタンガムおよびテルペノイドを含有する点眼剤 | |
MX2012008516A (es) | Agonista alfa-2 adrenergico que tiene larga duracion de efecto de baja presion intraocular. | |
JP5305710B2 (ja) | ドルゾラミド塩酸塩点眼液 | |
WO2017167457A1 (en) | Preservative free pharmaceutical composition for ophthalmic administration containing bimatoprost and timolol | |
WO2008056786A1 (fr) | Composition pour application cutanée ou par voie muqueuse | |
JP2015091867A (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用点眼剤 | |
WO2017151664A1 (en) | Pharmaceutical compositions for fluoroquinolone drug delivery | |
JP2009029779A (ja) | レボカバスチン及び/又はその塩を含有する水性医薬組成物 | |
US20160089375A1 (en) | Topical ocular analgesic agents | |
JP5258329B2 (ja) | プラノプロフェン含有水性医薬組成物 | |
JPH085779B2 (ja) | フレロキサシン点眼液 | |
JP2002205942A (ja) | 局所適用組成物 | |
JP4294276B2 (ja) | 点眼剤組成物 | |
BG64740B1 (bg) | Използване на гликогенен полизахарид като активенкомпонент за получавaнe на очен разтвор | |
EP4070796A1 (en) | Aqueous composition | |
CA2529860A1 (en) | Ophthalmic composition | |
EP2419081B1 (en) | Aqueous ophthalmic compositions containing anionic therapeutic agents | |
JP5460996B2 (ja) | 眼科用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110323 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130422 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130528 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130625 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5305710 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |